← Browse by Condition
Medical Condition

refractory chronic lymphocytic leukemia

Total Trials
6
Recruiting Now
6
Trial Phases
Phase 2, Phase 1
NCT04195633 Phase 2
Recruiting

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Enrollment
60 pts
Location
United States
Sponsor
Fred Hutchinson Cancer Center
View Trial →
NCT07099443
Recruiting

Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL

Enrollment
60 pts
Location
France
Sponsor
Nantes University Hospital
View Trial →
NCT04169737 Phase 2
Recruiting

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Enrollment
168 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
View Trial →
NCT05246345
Recruiting

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia

Enrollment
50 pts
Location
France
Sponsor
University Hospital, Clermont-...
View Trial →
NCT07061951 Phase 2
Recruiting

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

Enrollment
20 pts
Location
United States
Sponsor
National Cancer Institute (NCI...
View Trial →
NCT07166419 Phase 1
Recruiting

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Enrollment
24 pts
Location
United States
Sponsor
Ohio State University Comprehe...
View Trial →